A total of 1356 lung adenocarcinoma cases from April 2007 to May 2013 were sequenced for EGFR kinase domain mutations, KRAS mutations, HER2 kinase domain mutations, BRAF mutations, ALK fusions, ROS1 fusions, RET fusions and AKT1 mutations. This evidence concerns the gene KRAS and lung adenocarcinoma.